MedWatch reports: Another record year

Alphalyse is growing on all parameters

Alphalyse is having yet another record year, according to MedWatch, a business media covering the pharmaceutical and medtech industries:

Gross profit is increasing, profits are rising, and the number of employees is growing. But that's standard practice for Alphalyse.

The contract research organization, which offers protein analysis and identification of impurities in biological drugs, ended 2022 with a solid 27.4 percent gross profit increase compared to the previous year. This parameter sets a new record for Alphalyse once again.

In 2022, Alphalyse strengthened the company's focus on servicing key customers who develop and market new biological drugs.

At the same time, in 2022, Alphalyse received a GMP accreditation from the Danish Medicines Agency.

"This is of crucial importance in relation to our strategy to support our customers with HCP analysis throughout the development phase, and also for release testing when the drug is on the market," wrote management in the financial report.